NOTICE 1 페이지

NEWS & EVENT

Total 12 - 1 page

No	Subject	Date	Hit
12	Ildong Pharmaceutical Invests KRW 13,000,000,000 in iLeadBMS to Strengthen the Ecosystem of Novel Drug R&D	2021.07.15	8,247
익명 8,247 2021.07.15
11	Ildong Pharmaceutical Group’s ‘iLeadBMS’ Presents Non-Clinical Results of its Novel NASH Drug Candidate at the AASLD	2022.11.09	3,666
익명 3,666 2022.11.09
10	iLeadBMS Announces Results of TPD Molecular Glue Research of IL2106 (CDK12 Molecular Glue and Cyclin-K degrader) at ESMO TAT 2024	2024.02.27	4,507
익명 4,507 2024.02.27
9	iLeadBMS Announces Positive Preclinical Results of IL1512 (CXCR7 Agonist) at the ATS 2024	2024.05.21	3,549
익명 3,549 2024.05.21
8	iLeadBMS Announces Positive Liver Fibrosis Results of IL1512 (CXCR7 Agonist) at the EASL 2024	2024.07.10	3,236
익명 3,236 2024.07.10
7	iLeadBMS’ Cyclin-K Molecular Glue Receives ODD from FDA for Gastric Cancer	2024.10.07	4,127
익명 4,127 2024.10.07
6	iLeadBMS Presents Preclinical Data on Novel Drug Candidate for Heart Failure at AFDD	2024.11.21	2,721
익명 2,721 2024.11.21
5	iLeadBMS Announces Orphan Drug Designation Granted by the FDA for IL21120033 (CXCR7 Agonist) for Idiopathic Pulmonary Fibrosis	2025.02.13	3,138
익명 3,138 2025.02.13
4	iLeadBMS Presents Preclinical Data on IL21120033 for Heart Failure at ACC 2025	2025.03.31	3,304
익명 3,304 2025.03.31
3	iLeadBMS Presents Preclinical Data on IL21120033, a First-in-Class ACKR3 Ago-PAM at EULAR 2025	2025.06.14	3,580
익명 3,580 2025.06.14
2	신주발행공고	2025.12.29	1,737
익명 1,737 2025.12.29
1	신주발행공고	2026.03.12	2,233
익명 2,233 2026.03.12

1페이지

INVESTORS & MEDIA

INVESTORS & MEDIA

NEWS & EVENT